You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Sinovac launches clinical trial of vaccine on children, teenagers in SA

Chinese pharma company Sinovac Biotech on Friday launched the Phase III clinical trial of its Covid-19 vaccine on a group of children and teenagers between six months and 17 years old in South Africa

Topics
Coronavirus Vaccine | Coronavirus | South Africa

IANS  |  Johannesburg 

Sinovac, Vaccine

Chinese pharmaceutical company Sinovac Biotech on Friday launched the Phase III clinical trial of its Covid-19 vaccine on a group of children and teenagers between six months and 17 years old in

The study, carried out in collaboration with South African company Numolux Group, has enrolled approximately 2,000 participants in the country, who will receive two doses of Sinovac's CoronaVac vaccine or a placebo, 28 days apart. The efficacy assessment will be based on relevant indicators, the Xinhua news agency reported.

Numolux CEO Hilton Klein said that there are roughly 24 million children and teenagers in South Africa, and that if the vaccine made by Sinovac is approved for use on them, it will help the country reach herd immunity more quickly.

The South African Health Products Regulatory Authority authorised the use of the CoronaVac vaccine on the country's adults in July.

--IANS

int/rs

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, September 12 2021. 08:40 IST
RECOMMENDED FOR YOU